Flubromazolam is a triazolobenzodiazepine — a structural fusion of the triazolo ring system of alprazolam and triazolam with the fluorine and bromine substitution pattern of flubromazepam. This combination produces one of the most potent benzodiazepine-class compounds encountered in research chemical markets, with activity reported at doses of 0.05–0.5 mg (50–500 micrograms) — doses so small that inaccurate measurement creates serious overdose risk. Community members have described effects beginning at doses in the 50–100 microgram range; typical doses causing full sedation are in the 0.1–0.5 mg range.
The combination of very high potency, triazolo-ring-associated pronounced amnesia, and the extended duration inherited from its bromazepam-related parent structure creates an exceptionally dangerous compound for uncontrolled use. A small amount of powder on a scale could represent multiple active doses; the margin between an anxiolytic dose and one producing unconsciousness is narrow; and the amnestic effects mean users may not accurately recall what they consumed.
Two Reddit posts in the database touch on flubromazolam, reflecting its more niche use compared to etizolam or flualprazolam. The harm reduction community has consistently flagged flubromazolam as among the highest-risk designer benzodiazepines — not because its pharmacology is qualitatively different from other benzodiazepines, but because the combination of sub-milligram active doses, pronounced amnesia, and extended duration creates multiple compounding risks for even experienced benzodiazepine users.
Safety at a Glance
High Risk- Volumetric Dosing Only
- For example: 10 mg dissolved in 100 mL of 40% alcohol = 0.1 mg/mL solution. A 0.25 mL dose = 25 micrograms. This is t...
- Toxicity: Extreme Sub-Milligram Potency The most critical safety consideration for flubromazolam is its extreme potency. Active...
- Dangerous with: 1,4-Butanediol, 2M2B, Acetylfentanyl, Alcohol (+59 more)
- Overdose risk: overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not t...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 12 hrs – 18 hrsHow It Feels
Flubromazolam is measured in micrograms for good reason. Within twenty minutes of an active dose, the substance asserts itself with a force that is profoundly disproportionate to the tiny amount consumed. A wall of sedation slams into consciousness, and in its wake, anxiety, worry, and self-consciousness are simply obliterated. There is nothing gradual about this onset; it is a sudden, total restructuring of the mental landscape, as though someone had pressed a reset button on the nervous system.
The come-up is less an intensification than a deepening of the initial impact. The sedation becomes so thorough that staying awake requires active resistance, and for many, that resistance fails within the first hour. The muscles relax to the point of near-total flaccidity, and the body becomes an impossibly heavy thing, glued to whatever surface it rests upon. Speech degrades rapidly -- words slur, sentences lose their structure, and the effort required to communicate begins to seem pointless. There is a euphoria buried somewhere beneath the sedation, but it is like treasure at the bottom of a deep well: you know it is there, but reaching it requires more consciousness than you can currently muster.
At the peak, if you remain awake to experience it, the world is observed from behind several layers of insulation. Vision is blurred, sounds are muffled, and the emotional register has been compressed to a narrow band of uncritical acceptance. Memory ceases to function in any reliable way; the blackout is not a possibility but a near-certainty, and hours of experience can be erased as cleanly as chalk from a board. Motor coordination is so impaired that walking becomes genuinely dangerous, a stumbling, weaving negotiation with surfaces and obstacles. The disinhibition is total, and the combination of this disinhibition with complete amnesia is what makes this substance particularly treacherous.
The comedown, like the substance itself, is measured in excess. The sedation persists for many hours, often carrying through an entire night of sleep and into the following day. Waking brings a thick, disorienting grogginess and significant gaps in memory. The residual effects can linger for thirty-six hours or more, a long chemical shadow that slowly recedes.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(5)
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Cognitive & Perceptual Effects
Cognitive(8)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
Pharmacology
Mechanism of Action
Flubromazolam is a potent full agonist at the benzodiazepine binding site of GABA-A receptors. Like all benzodiazepine-class compounds, it acts as a positive allosteric modulator, potentiating GABA-mediated chloride conductance at GABA-A receptor complexes throughout the CNS.
Triazolobenzodiazepine Structure and Potency
The triazolo ring fused to the diazepine core — characteristic of alprazolam, triazolam, and related compounds — is associated with very high receptor binding affinity and potency, as well as particularly pronounced amnestic effects relative to non-triazolo benzodiazepines. The fluoro and bromo substituents further increase lipophilicity and receptor affinity.
The combined effect is a compound with potency estimated to be orders of magnitude above diazepam:
- Diazepam typical dose: 5–20 mg
- Alprazolam typical dose: 0.25–2 mg (~10x diazepam)
- Flubromazolam estimated active dose: 0.05–0.5 mg (~100–400x diazepam)
Duration
Despite the high potency suggesting a potentially shorter duration (as very potent compounds may bind and unbind quickly), flubromazolam inherits the structural characteristics producing extended half-life from its bromazolam-related pharmacophore. Duration is estimated at 12–18 hours, with residual effects potentially extending beyond 24 hours.
Amnesia
Triazolo ring compounds are characterized by particularly prominent anterograde amnesia. Flubromazolam has produced documented blackouts at recreational doses, sometimes extending to multiple hours of activity with no subsequent recall.
Detection Methods
Standard Drug Panel Inclusion
Flubromazolam is NOT detected on standard drug screening panels. This ultra-potent designer benzodiazepine, active at doses as low as 0.1 to 0.25 mg, was specifically designed with structural modifications that prevent detection by conventional immunoassay methods. Standard benzodiazepine immunoassay screens consistently produce false-negative results for flubromazolam, regardless of the concentration present. This compound is considered one of the most analytically challenging designer benzodiazepines.
Urine Detection
Flubromazolam and its metabolites are detectable in urine for approximately 3 to 7 days after a single dose. The primary urinary metabolites include hydroxylated and acetylated forms. Due to the extremely low doses consumed, absolute concentrations of the parent compound and metabolites in urine are very low, often in the low nanogram-per-milliliter range. Detection is only possible through LC-MS/MS methods specifically validated for this compound. Standard benzodiazepine urine confirmation panels do not include flubromazolam.
Blood and Serum Detection
Blood detection windows are 1 to 3 days. Active blood concentrations are typically below 5 ng/mL, with pharmacologically relevant concentrations as low as 0.5 ng/mL. The extreme potency means that blood concentrations associated with impairment or overdose are well below the limits of detection of routine toxicology methods. Specialized LC-MS/MS methods with sub-nanogram sensitivity are required.
Hair Follicle Detection
Hair detection is theoretically possible but extremely challenging due to the ultra-low doses consumed. Very few forensic laboratories have validated methods for flubromazolam in hair, and detection limits below 0.5 pg/mg of hair are required.
Confirmatory Methods
LC-MS/MS with high sensitivity is the only viable confirmatory approach. Reference standards are available from forensic chemistry suppliers but must be specifically requested. The compound is not included in standard designer drug panels at many laboratories. Emergency department clinicians should request comprehensive designer benzodiazepine screening when flubromazolam exposure is suspected.
Reagent Testing
Reagent testing is essentially useless for flubromazolam due to the sub-milligram doses involved. No colorimetric reagent can produce a visible reaction at the quantities typically found in a single dose. Fentanyl test strips are critically important for any product suspected to contain flubromazolam, as the designer benzodiazepine market has significant cross-contamination with synthetic opioids.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,4-Butanediol | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2M2B | Dangerous | Combined CNS depression; risk of respiratory failure |
| Acetylfentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Alcohol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Alprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Atropa belladonna | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Baclofen | Dangerous | Combined CNS depression; risk of respiratory failure |
| Benzodiazepines | Dangerous | Combined CNS depression; risk of respiratory failure |
| Buprenorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Cake | Dangerous | Combined CNS depression; risk of respiratory failure |
| Carisoprodol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonidine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Codeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Datura | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Deschloroetizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Desomorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Dextropropoxyphene | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Diclazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Dihydrocodeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diphenhydramine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Eszopiclone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Ethylmorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Etizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| F-Phenibut | Dangerous | Combined CNS depression; risk of respiratory failure |
| Fentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flualprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gabapentin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gaboxadol | Dangerous | Combined CNS depression; risk of respiratory failure |
| GBL | Dangerous | Combined CNS depression; risk of respiratory failure |
| GHB | Dangerous | Combined CNS depression; risk of respiratory failure |
| Grayanotoxin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Harmala alkaloid | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Heroin | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydrocodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydromorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Kratom | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Lorazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| MAOI | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Mephenaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Methadone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Methaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Metizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Midazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Mirtazapine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Morphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Myristicin | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Naloxone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Nicotine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Nifoxipam | Dangerous | Combined CNS depression; risk of respiratory failure |
| O-Desmethyltramadol | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxycodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxymorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Peganum harmala | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Pentobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| Pethidine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Phenobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| SAMe | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2-Aminoindane | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FEA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-Fluorodeschloroketamine | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-FMA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 1,3-Butanediol | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1B-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-AL-LAD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-MiPLA | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
History
Synthesis and Market Emergence
Flubromazolam appears to be a purpose-designed compound emerging in the novel psychoactive substances market, without prior pharmaceutical development history. It was first described in the research chemical literature around 2014–2015, appearing as an especially potent member of the second generation of designer benzodiazepines. Its design — combining the triazolobenzodiazepine scaffold of alprazolam/triazolam with the halogen substitution of flubromazepam — appears specifically intended to produce a high-potency, long-acting compound.
Harm Reduction Community Attention
Flubromazolam attracted significant attention from harm reduction communities precisely because its extreme potency created practical safety challenges that most recreational drug users were not equipped to manage. The compound became something of a test case for the limits of individual harm reduction practices: even users experienced with other benzodiazepines and careful about dosing found flubromazolam's sub-milligram active doses impossible to manage safely without specialized equipment.
Regulatory Status
Flubromazolam has been scheduled in Sweden, the United Kingdom, and several other European jurisdictions, as well as facing scheduling actions in other countries as part of broader responses to novel benzodiazepine proliferation.
Harm Reduction
Volumetric Dosing Only
Flubromazolam cannot be accurately weighed on any scale accessible to most individuals. The only safe dosing method is volumetric: dissolve a precisely measured quantity in a precisely measured volume of appropriate solvent (e.g., alcohol), then administer a precisely measured volume of the resulting solution. Even this method requires accurate preparation.
For example: 10 mg dissolved in 100 mL of 40% alcohol = 0.1 mg/mL solution. A 0.25 mL dose = 25 micrograms. This is the type of precision required.
Consider Avoiding This Compound Entirely
Given the combination of sub-milligram active doses, pronounced amnesia, and extended duration, flubromazolam represents a risk level that many experienced harm reduction practitioners recommend avoiding entirely. The incremental benefit over lower-potency alternatives does not justify the unique risks.
Never Use Alone
The amnesia and profound sedation potential means that a solo user who encounters adverse effects may be unable to call for help or be found. A sober observer who knows what substance was taken and can call emergency services is essential.
Do Not Combine with Any CNS Depressant
Zero tolerance for combination with alcohol, opioids, or other depressants. The potency makes any synergistic interaction potentially life-threatening.
Identify the Dose Before Any Use
Before any use, establish clearly: what concentration is the solution you've prepared, what volume are you administering, and what is the resulting dose. Write this down. Flubromazolam-induced amnesia means you may not remember the dose otherwise.
Toxicity & Safety
Extreme Sub-Milligram Potency
The most critical safety consideration for flubromazolam is its extreme potency. Active doses in the 50–500 microgram range are beyond the capability of any consumer-grade scale to measure accurately. A scale reading "0.1 g" (100 mg) for benzodiazepines is dangerously inaccurate — flubromazolam requires precision equipment or volumetric solution dosing, where even small errors in solution preparation can produce multiple-fold dosing errors.
Narrow Therapeutic Window
The dose range between anxiolytic effect and deep sedation/unconsciousness for flubromazolam appears narrow based on community reports. Slight over-dosing from inaccurate measurement can rapidly produce incapacitating sedation.
Anterograde Amnesia and Behavioral Risk
Blackouts from flubromazolam can occur at doses users describe as "normal." The combination of profound amnesia, continued behavioral capacity (users may appear awake), and inability to accurately assess or recall one's own degree of intoxication creates risk of additional consumption and dangerous behaviors during the amnestic period.
Respiratory Depression
Standard benzodiazepine respiratory depression risk applies, amplified by the high potency and narrow therapeutic window. Combination with alcohol or opioids is particularly dangerous.
Physical Dependence
Physical dependence develops with regular use. The potency means even very small regular doses can establish physical dependence.
Addiction Potential
extremely physically and psychologically addictive
Overdose Information
overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not treated promptly and properly. Symptoms of a benzodiazepine overdose may include severe thought deceleration, slurred speech, confusion, delusions, respiratory depression, coma or death. Benzodiazepine overdoses may be treated effectively in a hospital environment, with generally favorable outcomes. Benzodiazepine overdoses are sometimes treated with flumazenil, a GABAA antagonist, however care is primarily supportive in nature.
Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Depressants** (1,4-Butanediol, 2-methyl-2-butanol, alcohol, barbiturates, GHB/GBL, methaqualone, opioids) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Dissociatives** - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Stimulants** - It is dangerous to combine benzodiazepines with stimulants due to the risk of excessive intoxication. Stimulants mask the sedative
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Tolerance
| Full | within a couple of days of continuous use |
| Half | Unknown |
| Zero | 7 - 14 days |
Cross-tolerances
Legal Status
Flubromazolam is currently a gray area compound within most parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
Canada: All benzodiazepines are listed in Schedule IV.
Germany: Flubromazolam is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Poland: Flubromazolam is a NPS class drug in Poland, making it illegal to possess or distribute.
Russia: Flubromazolam is a Schedule III controlled substance since 2017.
Switzerland: Flubromazolam is a controlled substance specifically named under Verzeichnis E.
Turkey: Flubromazolam is a classed as drug and is illegal to possess, produce, supply, or import.
The Netherlands: Flubromazolam is a List 2 substance of the Opium Law, making it illegal.
United Kingdom: Flubromazolam is a Class C controlled substance as of May 31, 2017. It is illegal to possess, produce or supply.
United States: Flubromazolam is a Schedule I controlled substance as of January 23rd, 2023.
Responsible use
Volumetric liquid dosing
Research chemical
Depressants
Benzodiazepines
Flubromazolam (Wikipedia)
Flubromazolam (Isomer Design)
Experience Reports (1)
Tips (7)
Flubromazolam (sometimes called 'flam') is one of the most potent benzodiazepine analogues available. It produces intense amnesia and severe delusions of sobriety. People consistently report taking their intended dose, blacking out, and waking up days later with their entire supply gone. Use a timed lock box.
Flubromazolam is active at extremely low doses. A common starting dose is 0.125mg (125 micrograms). You absolutely need a milligram scale AND volumetric dosing to use this safely. Eyeballing this compound is how people lose weeks of their life to blackouts.
Never combine Flubromazolam with alcohol or opioids. This combination is responsible for a massive proportion of overdose deaths. The respiratory depression from mixing depressants is synergistic and unpredictable.
The only remotely safe way to dose flubromazolam is volumetric solution. Dissolve a known quantity in PG at a concentration like 0.5mg/ml and use a graduated oral syringe. Even then, prepare only what you intend to use for that session and store the rest locked away from your impaired self.
Research chemical benzodiazepines (clonazolam, flualprazolam, etc.) are significantly more potent than pharmaceutical Flubromazolam. Doses measured in micrograms can cause multi-day blackouts. Use volumetric dosing.
Test any Flubromazolam obtained outside a pharmacy. Counterfeit benzodiazepine pills (especially fake Xanax) frequently contain fentanyl, novel benzodiazepines like flualprazolam, or unpredictable doses. Use fentanyl test strips.
Community Discussions (1)
See Also
References (3)
- PubChem: Flubromazolam
PubChem compound page for Flubromazolam (CID: 21930924)
pubchem - Flubromazolam - TripSit Factsheet
TripSit factsheet for Flubromazolam
tripsit - Flubromazolam - Wikipedia
Wikipedia article on Flubromazolam
wikipedia